Leerink Transactions
$122 Million
Joint Bookrunner Initial Public Offering September 2018
$217 Million
Exclusive Financial Advisor Sale to Evolent Health Pending
$115 Million
Joint Bookrunner Follow-On September 2018
$150 Million
Joint Bookrunner Follow-On September 2018
$144 Million
Joint Bookrunner Follow-On August 2018
$312 Million
Joint Bookrunner Follow-On August 2018
$59 Million
Joint Bookrunner Follow-On July 2018
$248 Million
Joint Bookrunner Follow-On July 2018
$116 Million
Joint Bookrunner Initial Public Offering July 2018
$99 Million
Joint Bookrunner Follow-On July 2018
$277 Million
Joint Bookrunner Initial Public Offering July 2018
$117 Million
Joint Bookrunner Initial Public Offering July 2018
$166 Million
Joint Bookrunner Follow-On July 2018
$70 Million
Sole Bookrunner Follow-On July 2018
NZ$255 Million
Financial Advisor Recapitalization by Hg Pending
$126 Million
Joint Bookrunner Initial Public Offering June 2018
$77 Million
Sole Bookrunner Follow-On June 2018
$98 Million
Joint Bookrunner Initial Public Offering June 2018
$118 Million
Joint Bookrunner Initial Public Offering June 2018
$75 Million
Joint Bookrunner Follow-On May 2018
$53 Million
Bookrunning Manager Follow-On May 2018
$83 Million
Joint Bookrunner Initial Public Offering May 2018
$58 Million
Joint Bookrunner Follow-On May 2018
$141 Million
Joint Bookrunner Follow-On May 2018
$42 Million
Joint Bookrunner Initial NASDAQ Listing May 2018
$117 Million
Joint Bookrunner Follow-On May 2018
$147 Million
Joint Bookrunner Follow-On May 2018
$155 Million
Joint Bookrunner Follow-On May 2018
Undisclosed
Exclusive Financial Advisor Acquisition of Braintree Laboratories May 2018
Undisclosed
Exclusive Financial Advisor Sale to Dentsply Sirona Inc. May 2018
$160 Million
Joint Bookrunner Convertible Senior Subordinated Notes April 2018
$239 Million
Joint Bookrunner Initial NASDAQ Listing April 2018
$30 Million
Sole Placement Agent Registered Direct Offering April 2018
Undisclosed
Exclusive Financial Advisor Recapitalization by WCAS April 2018
Undisclosed
Exclusive Financial Advisor Sale to Boston Scientific April 2018
$110 Million
Joint Bookrunner Follow-On March 2018
$406 Million
Joint Bookrunner Follow-On March 2018
$260 Million
Joint Bookrunner Follow-On March 2018
Undisclosed
Exclusive Financial Advisor Sale to JLL Partners and Water Street Healthcare Partners March 2018
$138 Million
Joint Bookrunner Initial Public Offering March 2018
$614 Million
Lead Financial Advisor Acquisition of Cascadian Therapeutics March 2018
$314 Million
Co-Bookrunning Manager Follow-On February 2018
$144 Million
Lead Bookrunning Manager Exchangeable Senior Notes February 2018
$69 Million
Sole Bookrunner Follow-On February 2018
$288 Million
Joint Bookrunner Convertible Senior Notes January 2018
$144 Million
Joint Bookrunner Follow-On January 2018
$147 Million
Joint Bookrunner Initial Public Offering January 2018
$144 Million
Joint Bookrunner Initial Public Offering January 2018
$98 Million
Joint Bookrunner Initial Public Offering January 2018
$231 Million
Joint Bookrunner Follow-On January 2018
$115 Million
Joint Bookrunner Follow-On January 2018
$143 Million
Joint Bookrunner Follow-On January 2018
$58 Million
Joint Bookrunner Follow-On January 2018
$450 Million
Joint Bookrunner Convertible Senior Notes January 2018
$690 Million
Co-Manager Convertible Senior Notes January 2018
$40 Million
Joint Bookrunner Follow-On January 2018
$800 Million
Joint Bookrunner Follow-On January 2018
$67 Million
Financial Advisor Private Placement December 2017
$46 Million
Joint Bookrunner Follow-On December 2017
$46 Million
Joint Bookrunner Follow-On December 2017
$74 Million
Joint Bookrunner Initial Public Offering December 2017
Undisclosed
Exclusive Financial Advisor Sale to Quest Diagnostics December 2017
$102 Million
Joint Bookrunner Initial Public Offering November 2017
$41 Million
Sole Bookrunner Follow-On November 2017
$51 Million
Joint Bookrunner Secondary Offering November 2017
$106 Million
Joint Bookrunner Initial Public Offering November 2017
$150 Million
Joint Bookrunner Follow-On November 2017
$92 Million
Joint Bookrunner Follow-On October 2017
$91 Million
Joint Bookrunner Follow-On October 2017
Undisclosed
Exclusive Financial Advisor Acquisition of Tea Leaves Health October 2017
$69 Million
Joint Bookrunner Follow-On October 2017
$108 Million
Joint Bookrunner Follow-On October 2017
$289 Million
Joint Bookrunner Follow-On October 2017
$86 Million
Joint Bookrunner Initial Public Offering September 2017
$172 Million
Joint Bookrunner Follow-On September 2017
$230 Million
Joint Bookrunner Follow-On September 2017
$173 Million
Joint Bookrunner Initial Public Offering September 2017
$161 Million
Joint Bookrunner Follow-On September 2017
$403 Million
Joint Bookrunner Follow-On September 2017
$375 Million
Joint Bookrunner Follow-On August 2017
Undisclosed
Exclusive Financial Advisor Royalty Restructuring Transaction August 2017
$330 Million
Exclusive Financial Advisor Senior Credit Facilities Transaction with PNC & TCP August 2017
$57 Million
Joint Bookrunner Follow-On August 2017
$86 Million
Joint Bookrunner Follow-On August 2017
$80 Million
Exclusive Financial Advisor Acquisition of Exclusive WW Lebrikizumab License from Roche August 2017
$138 Million
Joint Bookrunner Initial Public Offering August 2017
$40 Million
Exclusive Financial Advisor Acquisition of Good Start Genetics July 2017
$73 Million
Placement Agent PIPE July 2017
$116 Million
Joint Bookrunner Follow-On July 2017
$223 Million
Exclusive Financial Advisor Private Placement July 2017
$46 Million
Sole Bookrunner Follow-On July 2017
$97 Million
Joint Bookrunner Follow-On July 2017
$70 MILLION + MILESTONES
Exclusive Financial Advisor Sale to Cotiviti July 2017
$173 Million
Joint Bookrunner Follow-On July 2017
$173 Million
Joint Bookrunner Follow-on July 2017
$86 Million
Joint Bookrunner Initial Public Offering June 2017
$75 Million
Joint Bookrunner Initial Public Offering June 2017
$41 Million
Sole Bookrunner Follow-On May 2017
$113 Million
Joint Bookrunner Follow-On May 2017
Undisclosed
Exclusive Financial Advisor Sale to Apax Partners May 2017
$288 Million
Joint Bookrunner Convertible Senior Notes May 2017
Undisclosed
Exclusive Financial Advisor Sale to Sheridan Capital Partners April 2017
$518 Million
Joint Bookrunner Convertible Senior Notes April 2017
Undisclosed
Exclusive Financial Advisor Acquisition of ArroHealth April 2017
$79 Million
Joint Bookrunner Follow-On April 2017
$85 Million
Joint Bookrunner Initial Public Offering April 2017
$100 Million
Joint Bookrunner Follow-On April 2017
$120 Million
Joint Bookrunner Follow-On April 2017
$200 Million
Exclusive Financial Advisor Sale to Sucampo April 2017
$1.65 Billion
Exclusive Financial Advisor Sale to Hologic March 2017
$349 Million
Co-Manager Follow-On March 2017
$66 Million
Joint Bookrunner Follow-On March 2017
$81 Million
Sole Bookrunner Follow-On March 2017
$173 Million
Joint Bookrunner Follow-On March 2017
$194 Million
Joint Bookrunner Follow-On March 2017
$97 Million
Joint Bookrunner Initial Public Offering January 2017
Undisclosed
Exclusive Financial Advisor Sale to Zydus Cadila January 2017
Undisclosed
Exclusive Financial Advisor Sale to Tailwind Capital January 2017
$150 Million
Joint Bookrunner Follow-On January 2017
$440 Million
Exclusive Financial Advisor Acquisition of Rights to Palatin Technologies' Rekynda January 2017
$69 Million
Sole Bookrunner Follow-On January 2017
$60 Million
Exclusive Financial Advisor Equity Investment from KKR December 2016
$300 Million
Sole Manager Convertible Senior Notes December 2016
Undisclosed
Financial Advisor Sale to Unilever December 2016
$250 Million
Joint Bookrunner Convertible Senior Notes December 2016
$101 Million
Joint Bookrunner Follow-On December 2016
$23 Million
Exclusive Placement Agent Series C Preferred Financing November 2016
$127 Million
Sole Bookrunner Follow-On November 2016
$57 Million
Exclusive Placement Agent Private Placement November 2016
$105 Million
Joint Bookrunner Follow-On November 2016
$236 Million
Joint Bookrunner Follow-On November 2016
$34 Million
Sole Bookrunner Follow-On November 2016
$230 Million
Joint Bookrunner Convertible Notes October 2016
$115 Million
Joint Bookrunner Follow-On October 2016
$169 Million
Co-Manager Follow-On September 2016
$76 Million
Joint Bookrunner Initial Public Offering September 2016
$75 Million
Joint Bookrunner Follow-On September 2016
$33 Million
Joint Bookrunner Follow-On September 2016
~$800 Million
Financial Advisor Sale to Horizon Pharma Pending
$75 Million
Joint Bookrunner Follow-On September 2016
$63 Million
Sole Bookrunner Follow-On August 2016
$93 Million
Joint Bookrunner Initial Public Offering August 2016
$168 Million
Exclusive Financial Advisor Convertible Note Exchange August 2016
$410 Million
Financial Advisor Sale to Myriad Genetics August 2016
$32 Million
Joint Bookrunner Follow-On July 2016
$719 Million
Co-Manager Initial Public Offering July 2016
$35 Million
Sole Bookrunner Follow-On July 2016
$433 Million
Joint Bookrunner Follow-On June 2016
$150 Million
Co-Manager Convertible Senior Notes June 2016
$64 Million
Joint Bookrunner Follow-On June 2016
$25 Million
Exclusive Placement Agent Private Placement June 2016
$145 Million
Joint Bookrunner Follow-On June 2016
$50 Million
Sole Bookrunner Follow-On May 2016
$124 Million
Joint Bookrunner Initial Public Offering May 2016
$115 Million
Joint Bookrunner Follow-On April 2016
$190 Million
Co-Manager Initial Public Offering April 2016
$85 Million
Exclusive Financial Advisor Sale to Allergan April 2016
Undisclosed
Exclusive Financial Advisor Sale to Alvogen April 2016
$144 Million
Joint Bookrunner Follow-On April 2016
$49 Million
Joint Bookrunner Follow-On March 2016
$185 Million
Exclusive Financial Advisor Acquisition of US Contrave Rights from Takeda March 2016
Undisclosed
Exclusive Financial Advisor European Commercialization Agreement with Valeant March 2016
$165 Million
Exclusive Financial Advisor Senior Secured Convertible Notes March 2016
$50 Million
Joint Bookrunner Initial Public Offering February 2016
$410 Million
Exclusive Financial Advisor Sale of Hemostasis Portfolio to Mallinckrodt plc February 2016
$86 Million
Joint Bookrunner Follow-On January 2016
Undisclosed
Exclusive Financial Advisor Sale to Consonance Capital Partners January 2016
$120 Million
Joint Bookrunner Follow-On January 2016
$150 Million
Joint Bookrunner Follow-On January 2016
$275 Million
Exclusive Financial Advisor Sale to NeoGenomics Laboratories December 2015
$34 Million
Co-Manager Follow-On December 2015
$50 Million
Exclusive Placement Agent Private Placement December 2015
CHF 60 Million
Exclusive Financial Advisor Private Placement November 2015
$23 Million
Exclusive Placement Agent Private Placement November 2015
$45 Million
Exclusive Financial Advisor Sale to Abcam plc November 2015
$102 Million
Joint Bookrunner Initial Public Offering November 2015
$50 Million
Joint Bookrunner Equity Offering November 2015
$93 Million
Joint Bookrunner Initial Public Offering September 2015
$44 Million
Joint Bookrunner Initial Public Offering September 2015
$847 Million
Exclusive Financial Advisor Acquisition of Scioderm September 2015
$66 Million
Co-Manager Follow-On September 2015
$345 Million
Joint Bookrunner Follow-On September 2015
$92 Million
Joint Bookrunner Initial Public Offering September 2015
$101 Million
Joint Bookrunner Follow-On September 2015
$37 Million
Sole Placement Agent Private Placement September 2015
$480 Million
Joint Bookrunner Follow-On September 2015
$98 Million
Joint Bookrunner Follow-On September 2015
$70 Million
Exclusive Placement Agent Private Placement August 2015
$42 Million
Exclusive Placement Agent Private Placement August 2015
$66 Million
Exclusive Placement Agent Private Placement August 2015
$111 Million
Joint Bookrunner Follow-On August 2015
$52 Million
Joint Bookrunner Follow-On August 2015
$98 Million
Joint Bookrunner Follow-On July 2015
$68 Million
Sole Bookrunner Convertible Senior Notes July 2015
$55 Million
Exclusive Placement Agent Private Placement July 2015
$40 Million
Joint Bookrunner Follow-On July 2015
$130 Million
Joint Bookrunner Follow-On July 2015
$282 Million
Joint Bookrunner Follow-On July 2015
€32 Million
Private Placement Exclusive Placement Agent July 2015
$212 Million
Financial Advisor Acquisition of Celsis International July 2015
$225 Million
Co-Manager Initial Public Offering June 2015
$103 Million
Co-Manager Follow-On June 2015
$276 Million
Co-Manager Follow-On June 2015
$230 Million
Joint Bookrunner Follow-On June 2015
$60 Million
Sole Placement Agent Private Placement June 2015
$48 Million
Joint Bookrunner Initial Public Offering June 2015
$137 Million
Joint Bookrunner Follow-On June 2015
$75 Million
Joint Bookrunner Follow-On June 2015
$78 Million
Sole Placement Agent PIPE June 2015
$1,290 Million
Co-Manager Follow-On May 2015
$35 Million
Joint Bookrunner Follow-On May 2015
$49 Million
Joint Bookrunner Follow-On May 2015
$25 Million
Sole Bookrunner Follow-On May 2015
$41 Million
Joint Bookrunner Follow-On May 2015
$50 Million
Sole Bookrunner Initial Public Offering May 2015
$191 Million
Joint Bookrunner Initial Public Offering May 2015
$76 Million
Joint Bookrunner Follow-On April 2015
$100 Million + Milestones
Exclusive Financial Advisor Sale of Zohydro to Pernix April 2015
$80 Million
Joint Bookrunner Follow-On April 2015
$137 Million
Joint Bookrunner Initial Public Offering April 2015
$77 Million
Joint Bookrunner Initial Public Offering April 2015
$89 Million
Joint Bookrunner Follow-On April 2015
$75 Million
Sole Bookrunner Initial Public Offering April 2015
$40 Million
Joint Bookrunner Follow-On April 2015
$98 Million
Joint Bookrunner Follow-On April 2015
Not Disclosed
Exclusive Financial Advisor Merger with Uroplasty to create Cogentix Medical March 2015
$238 Million
Joint Bookrunner Follow-On March 2015
$55 Million
Joint Bookrunner Follow-On March 2015
$285 Million
Co-Manager Follow-On March 2015
$64 Million
Joint Bookrunner Follow-On March 2015
$35 Million
Joint Bookrunner Follow-On March 2015
$152 Million
Joint Bookrunner Follow-On March 2015
$149 Million
Joint Bookrunner Follow-On March 2015
$139 Million
Joint Bookrunner Follow-On March 2015
$144 Million
Joint Bookrunner Follow-On March 2015
$58 Million
Lead Placement Agent Private Placement & Reverse Merger March 2015
$130 Million
Joint Bookrunner Follow-On March 2015
$192 Million
Joint Bookrunner Follow-On March 2015
$200 Million
Joint Bookrunner Follow-On February 2015
$123 Million
Sole Bookrunner Follow-On February 2015
$60 Million
Joint Bookrunner Initial Public Offering February 2015
$142 Million
Joint Bookrunner Follow-On February 2015
$117 Million
Co-Manager Initial Public Offering February 2015
$53 Million
Sole Bookrunner Follow-On January 2015
$52 Million
Joint Bookrunner Follow-On January 2015
$87 Million
Sole Bookrunner Follow-On January 2015
$124 Million
Joint Bookrunner Initial Public Offering January 2015
$138 Million
Joint Bookrunner Follow-On January 2015
$54 Million
Joint Bookrunner Follow-On January 2015
$5.2 Billion
Financial Advisor Sale to Shire January 2015
$204 Million
Joint Bookrunner Follow-On January 2015
$400 Million
Co-Manager Convertible Senior Note Offering January 2015
$84 Million
Joint Bookrunner Follow-On January 2015
$51 Million
Exclusive Placement Agent Private Placement January 2015
$145 Million
Co-Manager Initial Public Offering November 2014
$414 Million
Joint Bookrunner Follow-On November 2014
$168 Million
Joint Bookrunner Initial Public Offering November 2014
$199 Million
Co-Manager Initial Public Offering October 2014
$52 Million
Co-Manager Follow-On October 2014
$86 Million
Co-Manager Initial Public Offering October 2014
$133 Million
Joint Bookrunner Follow-On October 2014
$235 Million
Joint Bookrunner Initial Public Offering October 2014
$80 Million
Joint Bookrunner Initial Public Offering October 2014
$125 Million
Joint Bookrunner Initial Public Offering October 2014
$410 Million
Financial Advisor Sale to Daiichi-Sankyo September 2014
$1,025 Million
Lead Financial Advisor Acquisition of Lumara Health Maternal Health Business September 2014
$112 Million
Joint Bookrunner Initial Public Offering September 2014
$56 Million
Joint Bookrunner Initial Public Offering September 2014
Not Disclosed
Exclusive Financial Advisor Sale to Cynosure September 2014
$51 Million
Exclusive Placement Agent Series C Private Placement August 2014
$115 Million
Sole Bookrunner Follow-On August 2014
$325 Million
Co-Manager Convertible Senior Notes August 2014
$66 Million
Co-Manager Initial Public Offering August 2014
$134 Million
Exclusive Financial Advisor Series B Private Placement August 2014
$61 Million
Joint Bookrunner Initial Public Offering August 2014
$105 Million
Exclusive Financial Advisor Sale to Medtronic July 2014
$63 Million
Co-Manager Initial Public Offering July 2014
$65 Million
Joint Bookrunner Initial Public Offering July 2014
$60 Million
Joint Bookrunner Initial Public Offering July 2014
$42 Million
Joint Bookrunner Initial Public Offering July 2014
$70 Million
Sole Financial Advisor Convertible Notes & Amended Loan Agreement with HealthCare Royalty Partners July 2014
Not Disclosed
Exclusive Financial Advisor Merger with Paratek July 2014
$129 Million
Joint Bookrunner Follow-On June 2014
$63 Million
Joint Bookrunner Follow-On June 2014
€50 Million
Co-Placement Agent Private Placement June 2014
$110 Million
Joint Bookrunner Initial Public Offering June 2014
$69 Million
Joint Bookrunner Initial Public Offering June 2014
$205 Million
Joint Bookrunner Follow-On June 2014
$34 Million
Exclusive Placement Agent Private Placement June 2014
$88 Million
Joint Bookrunner Initial Public Offering May 2014
$1,495 Million
Co-Manager Initial Public Offering April 2014
$170 Million
Exclusive Financial Advisor Sale to The Medicines Company April 2014
€42 Million
Exclusive Placement Agent Private Placement April 2014
$36 Million
Financial Advisor & Placement Agent Merger & Series B Financing April 2014
$60 Million
Sole Bookrunner Initial Public Offering April 2014
$62 Million
Joint Bookrunner Follow-On April 2014
$55 Million
Joint Bookrunner Initial Public Offering April 2014
$179 Million
Financial Advisor Acquisition of Galapagos' Services Division March 2014
$55 Million
Sole Bookrunner Follow-On March 2014
$61 Million
Sole Manager Follow-On March 2014
$27 Million
Exclusive Placement Agent Series B Private Placement March 2014
$84 Million
Sole Advisor Acquisition of Ex-North America Rights from Bayer Consumer Care AG March 2014
$50 Million
Sole Bookrunner Follow-On March 2014
$35 Million
Exclusive Placement Agent Private Financing February 2014
$72 Million
Co-Manager Initial Public Offering February 2014
$94 Million
Co-Manager Follow-On February 2014
NOT DISCLOSED
Exclusive Financial Advisor Sale to Stryker February 2014
$52 Million
Lead Placement Agent Private Placement February 2014
$126 Million
Joint Bookrunner Follow-On February 2014
$138 Million
Joint Bookrunner Follow-On February 2014
$58 Million
Joint Bookrunner Initial Public Offering February 2014
$151 Million
Joint Bookrunner Follow-On February 2014
$92 Million
Joint Bookrunner Initial Public Offering February 2014
$124 Million
Joint Bookrunner Follow-On January 2014
$104 Million
Joint Bookrunner Initial Public Offering January 2014
$101 Million
Joint Bookrunner Follow-On January 2014
$61 Million
Co-Manager Follow-On January 2014
$138 Million
Joint Bookrunner Follow-On January 2014
$75 Million
Sole Advisor Global Strategic Partnership with Valeant Pharmaceuticals January 2014
$117 Million
Joint Bookrunner Follow-On January 2014
$34M+ $26M Milestones
Exclusive Financial Advisor Sale to AtriCure, Inc. December 2013
Not Disclosed
Exclusive Financial Advisor Global License & Option Agreement with Takeda Pharmaceutical Co. Ltd. December 2013
$155M + $1.8B Milestones
Exclusive Financial Advisor Collaboration with Celgene December 2013
$197 Million
Joint Bookrunner Follow-On December 2013
$115 Million
Joint Bookrunner Convertible Debt December 2013
$81 Million
Joint Bookrunner Initial Public Offering December 2013
$90 Million
Co-Manager Follow-On November 2013
$62 Million
Joint Bookrunner Follow-On November 2013
$125 Million
Joint Bookrunner Initial Public Offering November 2013
$69 Million
Joint Bookrunner Follow-On November 2013
$66 Million
Joint Bookrunner Initial Public Offering October 2013
$58 Million
Joint Bookrunner Follow-On October 2013
$92 Million
Joint Bookrunner Initial Public Offering October 2013
$134 Million
Joint Bookrunner Follow-On October 2013
$35 Million
Sole Bookrunner Follow-On September 2013
$122 Million
Co-Manager Initial Public Offering September 2013
$96 Million
Joint Bookrunner Initial Public Offering September 2013
$410 Million
Exclusive Financial Advisor Sale to Catamaran Corp August 2013
Not Disclosed
Exclusive Financial Advisor Sale to Cardinal Health August 2013
$65 Million
Joint Bookrunner Follow On August 2013
$201 Million
Joint Bookrunner Follow-On August 2013
$72 Million
Sole Bookrunner Follow On July 2013
$89 Million
Joint Bookrunner Initial Public Offering July 2013
$46 Million
Co-Manager Initial Public Offering July 2013
$64 Million
Joint Bookrunner Follow On July 2013
$94 Million
Joint Bookrunner Initial Public Offering July 2013
$54 Million
Co-Manager Initial Public Offering June 2013
Not Disclosed
Exclusive Financial Advisor Staged Sale to St. Jude Medical June 2013
Not Disclosed
Exclusive Financial Advisor In-licensing of commercial rights to MuGard from Access Pharmaceuticals June 2013
$89 Million
Joint Bookrunner Initial Public Offering May 2013
Not Disclosed
Exclusive Financial Advisor Sale of Transactional Business to GE Healthcare May 2013
$55 Million
Exclusive Placement Agent Private Placement May 2013
$65 Million
Joint Bookrunner Initial Public Offering May 2013
$83 Million
Joint Bookrunner Initial Public Offering May 2013
$110 Million
Exclusive Financial Advisor Sale to Jawbone April 2013
$64 Million
Joint Bookrunner Initial Public Offering April 2013
$24 Million
Exclusive Financial Advisor Sale to / Simultaneous Financing TranS1 Inc. March 2013
$35 Million
Lead Placement Agent PIPE March 2013
$294 Million
Exclusive Financial Advisor Acquisition of Palomar Medical Technologies March 2013
$40 Million
Sole Bookrunner Follow-On March 2013
$69 Million
Joint Bookrunner Follow-On March 2013
$30 Million
Exclusive Placement Agent Private Placement February 2013
$142 Million
Joint Bookrunner Follow-On February 2013
$104 Million
Joint Bookrunner Follow-On February 2013
$70 Million
Sole Bookrunner Initial Public Offering January 2013
$83 Million
Exclusive Financial Advisor Sale to Analogic Corporation January 2013
Not Disclosed
Exclusive Financial Advisor Sale of fiXate Tissue Band Assets to Boston Scientific January 2013
$34 Million
Joint Bookrunner Follow-On January 2013
Not Disclosed
Exclusive Financial Advisor Strategic Investment From Merck Global Health Innovation December 2012
Not Disclosed
Financial Advisor Strategic Investment From GE Healthymagination December 2012
$115M + Option to Purchase
Exclusive Financial Advisor Collaboration with BMS for Recothrom Bristol-Myers Squibb December 2012
$185M + Und. Earnout
Exclusive Financial Advisor Sale to The Medicines Company December 2012
$50 Million
Financial Advisor Royalty Financing Agreement with HealthCare Royalty Partners December 2012
Not Disclosed
Financial Advisor Sale to KCI November 2012
$230 Million
Exclusive Financial Advisor Sale to Sun Pharmaceutical Industries November 2012
$210 Million
Co-Lead Placement Agent Private Placement November 2012
$75 Million
Sole Bookrunner Follow-On November 2012
$61 Million
Joint Bookrunner Follow-On October 2012
$138 Million
Joint Bookrunner Follow-On October 2012
Undisclosed
Financial Advisor Minority Recap with West End Holdings & Clayton Associates September 2012
$110 Million
Exclusive Financial Advisor Sale to McKesson September 2012
$60 Million
Co-Manager Follow-On August 2012
$115 Million
Joint Bookrunner Initial Public Offering August 2012
Not Disclosed
Exclusive Financial Advisor Sale to Life Technologies July 2012
$58 Million
Joint Bookrunner Initial Public Offering July 2012
$38 Million
Joint Bookrunner Follow-On July 2012
$20 Million
Joint Bookrunner Follow-On June 2012
$87 Million
Joint Bookrunner Initial Public Offering June 2012
Not Disclosed
Exclusive Financial Advisor Collaboration Agreement with Roche June 2012
$30M + $50M Earnout
Exclusive Financial Advisor Sale to Teleflex June 2012
$16 Million
Sole Bookrunner Follow-On May 2012
$41 Million
Joint Bookrunner Follow-On April 2012
$60 Million
Joint Bookrunner Follow-On April 2012
$43 Million
Lead Placement Agent Private Placement April 2012
$108 Million
Co-Manager Initial Public Offering March 2012
$57 Million
Joint Bookrunner Follow-On March 2012
$66 Million
Joint Bookrunner Follow-On March 2012
$60 Million
Joint Bookrunner Follow-On February 2012
$58 Million
Joint Bookrunner Initial Public Offering February 2012
$63 Million
Joint Bookrunner Initial Public Offering January 2012
$50 Million
Joint Bookrunner Follow-On January 2012
$24 Million
Sole Bookrunner Follow-On January 2012
$16 Million
Sole Bookrunner Follow-On December 2011
$90 Million
Sole Bookrunner Follow-On December 2011
$37 Million
Sole Financial Advisor Series D Financing November 2011
$60 Million
Joint Bookrunner Follow-On September 2011
$82 Million
Joint Bookrunner Follow-On July 2011
$52 Million
Joint Bookrunner Follow-On July 2011
$75M + $200M Earnout
Financial Advisor Sale to Allergan July 2011
$65 Million
Joint Bookrunner Follow-On June 2011
$518 Million
Co-Manager Initial Public Offering June 2011
$25 Million
Financial Advisor Acquisition of Aesthetic Business of HOYA ConBio June 2011
$32 Million
Financial Advisor Royalty Financing Agreement with HealthCare Royalty Partners June 2011
Not Disclosed
Financial Advisor Sale of Parallax Assets to Neurotherm June 2011
$58 Million
Joint Bookrunner Follow-On June 2011
Not Disclosed
Financial Advisor Sale of Assets to Sedgwick CMS May 2011
$114 Million
Joint Bookrunner Follow-On April 2011
$4.4 Billion
Co-Manager Initial Public Offering March 2011
$86 Million
Co-Manager Initial Public Offering February 2011
$86 Million
Joint Bookrunner Initial Public Offering February 2011
$45 Million
Joint Bookrunner Follow-On January 2011
$50 Million
Joint Bookrunner Follow-On January 2011
$105 Million
Joint Bookrunner Follow-On January 2011
$58 Million
Joint Bookrunner Initial Public Offering November 2010
$55 Million
Joint Bookrunner Initial Public Offering October 2010
Not Disclosed
Exclusive Financial Advisor Acquisition of Discus Dental October 2010
$50 Million
Joint Bookrunner Initial Public Offering August 2010
$2.5 Billion
Co-Manager Convertible Debt July 2010
$85M + $250M Earnout
Financial Advisor Sale to Hologic July 2010
$105 Million
Exclusive Financial Advisor Acquisition of Helixis July 2010
$329 Million
Financial Advisor Sale to Covidien June 2010
$30 Million
Joint Bookrunner Initial Public Offering April 2010
$99 Million
Joint Bookrunner Follow-On March 10
$34 Million
Sole Bookruner Follow-On January 2010
$130 Million
Financial Advisor Acquisition of Diagnostic Hybrids January 2010
$97 Million
Sole Bookrunner Follow-On January 2010
$29 Million
Financial Advisor Sale to Sciele (A Shionogi Company) November 2009
$199 Million
Joint Bookrunner Initial Public Offering October 2009
$85 MILLION
Financial Advisor Sale to Gen-Probe October 2009
$49 Million
Sole Bookrunner Follow-On September 2009
$288 Million
Financial Advisor Sale to Leo Pharma September 2009
$68 Million
Financial Advisor Merger with Candela September 2009
$398 Million
Financial Advisor Tender Offer to Acquire Facet Biotech September 2009
$50 Million
Sole Agent Private Placement September 2009
$23 Million
Sole Bookrunner Follow-On August 2009
$86 Million
Sole Bookrunner Follow-On July 2009
$1.0 Billion
Financial Advisor Fairness Opinion in Sale to Johnson & Johnson May 2009